Aurora Cannabis has completed a major expansion of its German manufacturing facility, more than doubling the site's annual flower production capacity in a multimillion-dollar bet on European medical cannabis demand.
The Edmonton-based company's upgraded EU-GMP certified facility in Leuna, Germany, represents a strategic play in one of the world's fastest-growing medical cannabis markets. Germany has emerged as Europe's largest medical cannabis market by volume, with patient numbers climbing steadily since the country liberalized access in 2017.
The numbers tell the story: Aurora's expanded production footprint positions the company to capture a larger share of European demand as medical cannabis programs mature across the continent. Germany alone has over 300,000 registered medical cannabis patients, and that figure has grown by double digits annually.
The European Opportunity
Aurora's investment comes as European cannabis companies face a critical choice—scale up domestic production or continue importing from lower-cost jurisdictions. The company's decision to expand in Germany signals confidence that EU-GMP certification and local production will command premium pricing despite higher operating costs.
EU-GMP (European Union Good Manufacturing Practice) certification is the gold standard for pharmaceutical-grade cannabis in Europe. Products meeting these strict quality standards can be sold across EU member states, giving Aurora access to markets from Poland to Portugal.
The Leuna facility expansion also hedges against potential regulatory shifts. Several European countries are considering tightening import restrictions or implementing domestic production requirements, making local capacity increasingly valuable.
Market Positioning
Aurora has struggled in its home Canadian market, where oversupply and price compression have squeezed margins across the industry. The company posted a net loss of CAD $70.8 million in its most recent quarter, though it has made progress reducing operating expenses.
Europe offers a different dynamic. Medical-only markets typically maintain higher price points than adult-use systems, and Germany's pharmacist-dispensed model has kept pricing relatively stable. Market watchers note that Aurora's European revenue has grown while its Canadian sales have declined.
The facility expansion also supports Aurora's pharmaceutical partnerships. The company supplies several European pharmaceutical distributors and has positioned itself as a bulk supplier to other licensed producers across the continent.
What's Next
Germany's cannabis policy is in flux, with the government having passed partial legalization legislation earlier this year. While adult-use sales through commercial retailers remain prohibited, the reforms have increased awareness and could drive more patients into the medical program.
Aurora's expanded capacity will come online as several other European markets—including the Czech Republic and Switzerland—advance their own medical cannabis frameworks. The company has not disclosed specific production volume targets for the upgraded facility.
The investment reflects a broader trend of Canadian licensed producers refocusing on international medical markets after the domestic adult-use market failed to meet early growth projections. Several competitors have made similar moves, though few have committed capital to facility expansions at Aurora's scale.
This article is based on original reporting by www.cannabisbusinesstimes.com.
